The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile
Abstract
We investigated the effects of chronic treatment with the CB1 receptor antagonist rimonabant (10 mg/kg/day p.o. for 10 weeks) in mice with established obesity (5‐month high‐fat diet). Untreated obese mice showed a weight gain of 46% (45.0 ± 0.6 g vs. 30.8 ± 0.5 g) compared with age‐matched animals fed a standard diet. Rimonabant treatment, commencing after 5‐month high‐fat diet, produced a marked and sustained decrease in body weight (34.5 ± 0.8 g vs. 47.2 ± 0.5 g in the high‐fat vehicle group, p < 0.001). The anti‐obesity effect of rimonabant was similar to that obtained by switching obese mice from high‐fat diet to standard laboratory diet during 10 weeks (final weight 33.7 ± 0.6 g) and was associated with only transient (14 days) reduction in energy intake. Serum leptin, insulin and glucose levels were markedly elevated in obese animals. Rimonabant treatment significantly reduced these elevations (leptin −81%, insulin −78%, glucose −67%, p < 0.001 in all cases vs. high‐fat vehicle group). In addition, rimonabant treatment modestly but significantly increased serum adiponectin levels (+18%, p < 0.05 vs. high‐fat vehicle group). Obese mice demonstrated abnormal serum lipid profiles. Although rimonabant did not modify high‐density lipoprotein cholesterol (HDLc) and had modest effects on total cholesterol, it significantly reduced triglycerides and low‐density lipoprotein cholesterol (LDLc) and, notably, increased the HDLc/LDLc ratio (12.4 ± 0.8 vs. 7.9 ± 0.2 in high‐fat vehicle group, p < 0.001). Therefore, in a model of established obesity, chronic rimonabant treatment produces a marked and sustained decrease in body weight (equivalent to that achieved by dietary change) which is associated with favourable modifications in serum biochemical and lipid profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Endocannabinoid control of food intake and energy balance
Di Marzo, V., & Matias, I. (2005) · Nature Neuroscience · doi:10.1038/nn1457 · Cited by 743
Matias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
Metadata
- Authors
- Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2004-11-10
- Volume
- 7
- Issue
- 1
- Pages
- 65-72
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1997133986
- Cited by
- 203
- References
- 4
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00374.x
- The paper
- Poirier, B., Bidouard, J. ‐., Cadrouvele, C., Marniquet, X., Staels, B., O'Connor, S. E., Janiak, P., & Herbert, J. ‐. (2005). The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00374.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.